Publications by authors named "Manuelle-Anne Viguier"
Article Synopsis
- Sézary syndrome is a rare and deadly skin cancer, and this study looked into the survival rates and factors affecting outcomes, particularly focusing on the treatment mogamulizumab.
- *The research analyzed data from 339 patients diagnosed between 2000 and 2020 across Europe, highlighting that age over 80 and large-cell transformation worsened survival rates.
- *Results indicated that patients treated with mogamulizumab had significantly lower mortality rates, suggesting it is an effective treatment option for Sézary syndrome.
Background: New skin and soft tissue infections (SSTI) guidelines were published in 2019 in France, changing the recommended duration for antibiotic treatment. The objective of the present study was to assess the impact of the publication of the 2019 French guidelines on SSTIs on the duration of antibiotic prescription for erysipelas.
Methods: In a before-after study (a year before and a year after April 1st, 2019), we included all adult patients diagnosed with erysipelas in Reims University Hospital medical wards and the emergency department.
Article Synopsis
- The study evaluated the effectiveness and safety of the drug omalizumab for treating bullous pemphigoid (BP) in patients who did not respond to standard treatments, analyzing data from 100 patients across 18 medical centers in France from 2014 to 2021.
- 77% of patients achieved complete remission (CR), and 9% achieved partial remission, with a median time to CR of approximately 3 months, although 14% experienced relapses within a median follow-up of 12 months.
- Higher baseline levels of anti-BP180-NC16A IgE were linked to better CR outcomes, while other factors like urticarial lesions or eosinophil
Background: Generalized pustular psoriasis (GPP) is a rare inflammatory skin disease with a considerable clinical burden. In the Effisayil™ 1 study, spesolimab, an anti-interleukin-36 receptor monoclonal antibody, demonstrated efficacy in treating GPP flares.
Objectives: To evaluate patient-reported outcomes (PROs) of patients with GPP who were treated with intravenous (IV) spesolimab 900 mg in the Effisayil™ 1 study.